When you draw to the "50" mark, you have drawn 0.5 mL
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
What they found: In the control group 70 % of rats died within 30 days In the BPC-157 group only 10 % died Histology: faster formation of collaterals, normalization of portal vein pressure, 80 % reduction in liver thromboses Why it matters: These are extreme conditions
At SoCal UC, we are committed to providing personalized, high-quality care, and our approach to IV hydration reflects this commitment